biostudies-literatureUnknown11(3)Foster GR<h4>Background</h4>Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice.<h4>Methods</h4>A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the impact of sr-RD on SVR24 (HCV RNA <50 IU/mL) were conducted in 951 Caucasian, noncirrhotiPloS onee0151703https://www.ebi.ac.uk/biostudies/studies/S-EPMC4809570biostudies-literatureImpact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort.PMC4809570Foti GPicciotto ABasho JGUARD-C Study GroupTundo PAugustyniak KSzlauer BFoster GRBocakova JBanyai TLipczynski AAmedea ABevanda MVarkonyi ID'angelo SCorrea MCVafiadi-Zoubouli ICattelan AMFabri MDi Perri GSaracco GMBrixko CJesic RVaczi ZComan FSharara AGomide GDimitroulopoulos DDeron ZTsianos EFaria TSilva GNikolopoulou VVerhaz AHoste PBandiera FColombo SColombo MGuessab NRizzetto MPirisi MSilaghi RAfredj NAmoroso PParikh SMartins Junior ECastellacci RMemon SGeorge CMansinho KNagy IErne EReddy KRBrunetto MOrfanou EEnyedi JPascu OTolvaj GFernandes JCDrenaggi DGietka AMazur WRamos JPGiguere AHorsmans YMatarazzo FMerat SShiffman MLTeixeira RPhilip MPigozzi MGArama VSporea IVarghese RRusso FPRao PVinelli FMulkay JPManesis EWarakomska ILengyel GNagral AAlavian SMMusialik JIvanovski LNemesanszky EAkriviades EDelic DNozic DJoksimovic NTornai IBastens BPereira PBiglino AReynaert HMousoulis GCasinelli KPeixe PBaka-Cwierz BMalhado JMusat MVerucchi GRadowska DDrakoulis CRizzardini GLee YNTrifan AMahiou HLuaia RMacedo GDi Giacomo AMangia AWarzee PMesihovic RLawate PHunyady BRached AAEvgenidis NLaukens PHausinger PKetikoglou ISood AHoloman JNagorni ASoardo GYaghi CHoumani ZDecaestecker JSpinzi GZali MRCurescu MAhn SHGabr MRacz IGanga RKrkoska DPieri AAl Ghandoor ZBerak HMello CEOltman MHalota WAbbas ZOlszok ISerejo FGheorghe LTallarico LFried KRuiz FJSzantova MMegna ASNevens FAhmetagic SKaragiannis IMakkai EEsmat GCosta CMontalbano MGuerreiro HRussello MAbdou AMBourgeois SAlberto STusnadi AJanssens FSzalay FLivia HMontalto GLasser LMemoli MDerbala MHanno AAndreoni MVincze AAl Qameesh JHassanein TStan MPiekos TSabusco GIbrahimpasic NElefsiniotis IAskar HLyra AAcalovschi MRobaeys GGiannoulis GMimidis KRibiczey PBellantani SSieklucki JChiriaco PMela MShabanaj GManolakopoulos SIonita-Radu FJankovic GPassariello NPatai AServais BMazzeo MLanglet PCalkic LDe Galocsy CMendes CSarmento-Castro RStanciu CVinci MVelez JOrlandini ASchneider FDaryani NEFerrari CGervain JSzentgyorgyi LKaratapanis SVarga MLefebvre VSilva MHMasood SMohsin ASomani SAl Gharabally AFlisiak RHarxhi AMonteverde CKonstantinovic LMahindad NVan Vlierberghe HLesch MKim YRoxo FLencu MDelwaide JColletta CBakalos GBunganic ISimon KCoppola CPreotescu LNassiri-Toosi MSprengers DSchreter IBellati GBassi PPietrangelo AHan SYCaruntu FMartinet JPVan Der Meersch FYang JD'amico EAssene CBhalla ARapaccini GLMotoc AAttili AFJablkowski MMichielsen PSantantonio TFierbinteanu-Braticevici CValente CYousry ABruno SSchuller JAissaoui MZignego ALSkladany LHenrion JCastelli FAleixo MJStreinu-Cercel ARaimondo GLakner LFrancisci DHashmi ZPaik SWKupcova VAscione AZaarour FOzsvar ZJarcuska POlteanu DAndreica VFerraz MLKanatakis SDemelia LQuirino TPelemis MJuriens IFerenci PZuin MOrszulak GCraxi ADebzi NMiftode EAncuta ITodorovic ZOmar ASvorcan PCijevschi CAhlers SCool MPiekarska AMazzella GDohaibi AfalseImpact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort.<h4>Background</h4>Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice.<h4>Methods</h4>A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the impact of sr-RD on SVR24 (HCV RNA <50 IU/mL) were conducted in 951 Caucasian, noncirrhoti2016-01-01T00:00:00Z20162026-05-04T16:36:05.308Z2019-03-26T22:57:40ZS-EPMC48095702701898810.1371/journal.pone.0151703